This Article Full Text Full Text (PDF) All Versions of this Article: 90/9/5015    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krebs, L. J. Articles by Arnold, A. Search for Related Content PubMed PubMed Citation Articles by Krebs, L. J. Articles by Arnold, A. Related Collections Calcium and Bone Metabolism Endocrine Oncology

HRPT2 Mutational Analysis of Typical Sporadic Parathyroid Adenomas

Center for Molecular Medicine (L.J.K., T.M.S., A.A.), Division of Endocrinology and Metabolism (A.A.), University of Connecticut Health Center, Farmington, Connecticut 06030-3101

Address all correspondence and requests for reprints to: Dr. Andrew Arnold, Center for Molecular Medicine, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, Connecticut 06030-3101. E-mail: molecularmedicine{at}uchc.edu.

Context: Mutations of HRPT2 are frequent in sporadic parathyroid carcinomas and central to their pathogenesis. However, the potential diagnostic utility of HRPT2 mutation status to distinguish between parathyroid carcinoma and adenoma hinges on the frequency of HRPT2 mutations in benign adenomas. Even a low rate of HRPT2 mutation in adenomas would greatly alter diagnostic specificity, because adenomas are far more prevalent than carcinomas. The issue remains open because of the limited number of typical adenomas, not subjected to additional selection criteria, examined in previous studies.

Objective/Design/Patients: To determine the frequency of HRPT2 somatic mutations in a substantial series of typical, sporadic parathyroid adenomas, we directly sequenced coding and flanking splice junctional regions of all HRPT2 exons in solitary adenomas from 60 patients.

Results/Conclusions: No intragenic HRPT2 mutations were detected, strengthening the degree of specificity of HRPT2 mutation as a feature of sporadic parathyroid carcinoma as opposed to sporadic adenomas. Our observations encourage additional study of the diagnostic potential of HRPT2 in parathyroid neoplasia and support the view that HRPT2 inactivation is not an important participant in the pathogenesis of typical parathyroid adenomas.

This article has been cited by other articles:

				C C Juhlin, A Villablanca, K Sandelin, F Haglund, J Nordenstrom, L Forsberg, R Branstrom, T Obara, A Arnold, C Larsson, et al. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification Endocr. Relat. Cancer, June 1, 2007; 14(2): 501 - 512. [Abstract] [Full Text] [PDF]

				F. Cetani, E. Ambrogini, P. Viacava, E. Pardi, G. Fanelli, A. G. Naccarato, S. Borsari, M. Lemmi, P. Berti, P. Miccoli, et al. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur. J. Endocrinol., May 1, 2007; 156(5): 547 - 554. [Abstract] [Full Text] [PDF]

				F. Raue and K. Frank-Raue Primary hyperparathyroidism--what the nephrologist should know--an update Nephrol. Dial. Transplant., March 1, 2007; 22(3): 696 - 699. [Full Text] [PDF]

				S. J. Marx and W. F. Simonds Imaging to detect early endocrine cancers. J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2861 - 2863. [Full Text] [PDF]

				C Juhlin, C Larsson, T Yakoleva, I Leibiger, B Leibiger, A Alimov, G Weber, A Hoog, and A Villablanca Loss of parafibromin expression in a subset of parathyroid adenomas. Endocr. Relat. Cancer, June 1, 2006; 13(2): 509 - 523. [Abstract] [Full Text] [PDF]